The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression

Kui Ming Chan(University of California, San Francisco), Dong Fang(University of California, San Francisco), Haiyun Gan(University of California, San Francisco), Rintaro Hashizume(University of California, San Francisco), Chuanhe Yu(University of California, San Francisco), Mark A. Schroeder(Mayo Clinic), Nalin Gupta(University of California, San Francisco), Sabine Mueller(University of California, San Francisco), C. David James(University of California, San Francisco), Robert B. Jenkins(Mayo Clinic), Jann N. Sarkaria, Zhiguo Zhang(University of California, San Francisco)
Genes & Development
April 19, 2013
10.1101/gad.217778.113
Cited by 702Open Access
Full Text

Abstract

Recent studies have identified a Lys 27-to-methionine (K27M) mutation at one allele of H3F3A, one of the two genes encoding histone H3 variant H3.3, in 60% of high-grade pediatric glioma cases. The median survival of this group of patients after diagnosis is ∼1 yr. Here we show that the levels of H3K27 di- and trimethylation (H3K27me2 and H3K27me3) are reduced globally in H3.3K27M patient samples due to the expression of the H3.3K27M mutant allele. Remarkably, we also observed that H3K27me3 and Ezh2 (the catalytic subunit of H3K27 methyltransferase) at chromatin are dramatically increased locally at hundreds of gene loci in H3.3K27M patient cells. Moreover, the gain of H3K27me3 and Ezh2 at gene promoters alters the expression of genes that are associated with various cancer pathways. These results indicate that H3.3K27M mutation reprograms epigenetic landscape and gene expression, which may drive tumorigenesis.

Related Papers

No related papers found

Powered by citation graph analysis